Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas.
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
J Urol. 2021 Jan;205(1):137-144. doi: 10.1097/JU.0000000000001337. Epub 2020 Aug 28.
Current serum tumor markers for testicular germ cell tumor are limited by low sensitivity. Growing evidence supports the use of circulating miR-371a-3p as a superior marker for malignant (viable) germ cell tumor management. We evaluated the real-world application of serum miR-371a-3p levels in detecting viable germ cell tumor among patients undergoing partial or radical orchiectomy.
Serum samples were collected from 69 consecutive patients before orchiectomy. Performance characteristics of serum miR-371a-3p were compared with conventional serum tumor markers (⍺-fetoproteinβ-human chorionic gonadotropinlactate dehydrogenase) between patients with viable germ cell tumor and those without viable germ cell tumor on orchiectomy pathology. Relative miR-371a-3p levels were correlated with clinical course. The Kruskal-Wallis test and linear and ordinal regression models were used for analysis.
For detecting viable germ cell tumor, combined conventional serum tumor markers had a specificity of 100%, sensitivity of 58% and AUC of 0.79. The miR-371a-3p test showed a specificity of 100%, sensitivity of 93% and AUC of 0.978. Median relative expression of miR-371a-3p in viable germ cell tumor cases was more than 6,800-fold higher than in those lacking viable germ cell tumor. miR-371a-3p levels correlated with composite stage (p=0.006) and, among composite stage I cases, independently associated with embryonal carcinoma percentage (p=0.0012) and tumor diameter (p <0.0001). Six patients underwent orchiectomy after chemotherapy and were correctly predicted to have presence or absence of viable germ cell tumor by the miR-371a-3p test.
If validated, the miR-371a-3p test can be used in conjunction with conventional serum tumor markers to aid clinical decision making. A positive miR-371a-3p test in patients after preoperative chemotherapy or with solitary testes could potentially guide subsequent orchiectomy or observation.
目前用于睾丸生殖细胞肿瘤的血清肿瘤标志物存在灵敏度低的局限性。越来越多的证据支持使用循环 miR-371a-3p 作为恶性(有活力的)生殖细胞肿瘤管理的更佳标志物。我们评估了血清 miR-371a-3p 水平在检测接受部分或根治性睾丸切除术的患者中是否存在有活力的生殖细胞肿瘤的实际应用。
在睾丸切除术之前,收集了 69 例连续患者的血清样本。在睾丸切除术病理上有或无有活力的生殖细胞肿瘤的患者之间,比较了血清 miR-371a-3p 与常规血清肿瘤标志物(α-胎蛋白、β-人绒毛膜促性腺激素、乳酸脱氢酶)的性能特征。相对 miR-371a-3p 水平与临床过程相关。使用 Kruskal-Wallis 检验和线性和有序回归模型进行分析。
对于检测有活力的生殖细胞肿瘤,联合使用常规血清肿瘤标志物的特异性为 100%,敏感性为 58%,AUC 为 0.79。miR-371a-3p 检测的特异性为 100%,敏感性为 93%,AUC 为 0.978。有活力的生殖细胞肿瘤病例中 miR-371a-3p 的中位相对表达量比缺乏有活力的生殖细胞肿瘤的病例高 6800 多倍。miR-371a-3p 水平与综合分期相关(p=0.006),在综合分期 I 病例中,与胚胎癌百分比独立相关(p=0.0012)和肿瘤直径(p<0.0001)。6 例患者在化疗后接受了睾丸切除术,miR-371a-3p 检测正确预测了这些患者是否存在有活力的生殖细胞肿瘤。
如果得到验证,miR-371a-3p 检测可以与常规血清肿瘤标志物联合使用,以辅助临床决策。在接受术前化疗或只有一个睾丸的患者中,miR-371a-3p 检测阳性可能有助于指导随后的睾丸切除术或观察。